University of Alabama at Birmingham (UAB) Hospital 35233 Birmingham United StatesRekrutierend» Google-MapsMayo Clinic Arizona 85054 Phoenix United StatesRekrutierend» Google-MapsCity of Hope Comprehensive Cancer Center 91010 Duarte United StatesRekrutierend» Google-MapsUCLA Medical Center 90095 Los Angeles United StatesRekrutierend» Google-MapsStanford Cancer Institute 94305 Stanford United StatesRekrutierend» Google-MapsGaliz Research 33016 Hialeah United StatesZurückgezogen» Google-MapsWinship Cancer Institute - Emory University 30322 Atlanta United StatesRekrutierend» Google-MapsRush University Medical Center 60612 Chicago United StatesRekrutierend» Google-MapsDana-Farber Cancer Institute 02215 Boston United StatesRekrutierend» Google-MapsColumbia University Irving Medical Center 10032 New York United StatesZurückgezogen» Google-MapsCleveland Clinic Taussig Cancer Center 44106 Cleveland United StatesRekrutierend» Google-MapsMUSC Health University Medical Center 29425 Charleston United StatesRekrutierend» Google-MapsThe University of Texas MD Anderson Cancer Center 77030 Houston United StatesRekrutierend» Google-MapsHuntsman Cancer Institute - University of Utah Health 84112 Salt Lake City United StatesRekrutierend» Google-MapsNepean Hospital 2747 Kingswood AustraliaRekrutierend» Google-MapsGold Coast University Hospital 4215 Southport AustraliaRekrutierend» Google-MapsPeter MacCallum Cancer Centre 3051 Melbourne N. AustraliaRekrutierend» Google-MapsAKH Wien, Universitatsklinikum 1090 Vienna AustriaRekrutierend» Google-MapsCHU de Liege 4000 Liège BelgiumRekrutierend» Google-MapsUniversity of Alberta Hospital T6G 2G3 Edmonton CanadaRekrutierend» Google-MapsSt. Michael's Hospital - Unity Health Toronto M5B 1W8 Toronto CanadaRekrutierend» Google-MapsCentre Hospitalier Universitaire (CHU) de Poitiers 86000 Poitiers FranceRekrutierend» Google-MapsCentre Hospitalier Universitaire (CHU) de Toulouse 31300 Toulouse FranceRekrutierend» Google-MapsIRCCS Azienda Ospedaliero Universitaria di Bologna 40138 Bologna ItalyRekrutierend» Google-MapsUniversity Medical Center Groningen 9713 Groningen NetherlandsRekrutierend» Google-MapsOslo University Hospital 0450 Oslo NorwayRekrutierend» Google-MapsHospital Universitario Vall d'Hebron 08740 Barcelona SpainRekrutierend» Google-MapsInstitut Català d'Oncologia - Hospital Duran i Reynals 08908 Barcelona SpainRekrutierend» Google-MapsHospital Universitario Ramón y Cajal 28034 Madrid SpainRekrutierend» Google-MapsUniversitätsspital Basel 4031 Basel SwitzerlandRekrutierend» Google-MapsUniversity College London Hospital - NHS Foundation Trust NW1 2BU London United KingdomRekrutierend» Google-MapsGuy's Hospital - NHS Foundation Trust SE1 9RT London United KingdomRekrutierend» Google-Maps
1. Part I: Identify clinically active and tolerable exposures of bezuclastinib in patients with AdvSM (Time Frame - 18 months)
2. Part II: - Determine efficacy of bezuclastinib as measured by mIWG Objective Response Rate (ORR) - Confirm the exposure-response relationship of bezuclastinib (Time Frame - 18 months)
2. Safety of CGT9486 as assessed by incidence of Adverse Events (AEs) (Time Frame - 18 months): Incidence of AEs according to CTCAE version 5.0 or higher
3. To determine the effects of bezuclastinib on mutation allele burden. (Time Frame - 18 months): Percentage change in KIT D816V
4. To determine the effects of bezuclastinib on serum tryptase. (Time Frame - 18 months): Percentage change in Serum Tryptase
5. To assess the pharmacokinetics of bezuclastinib in subjects with AdvSM. (Time Frame - 18 months): Percentage change in plasma concentrations of bezuclastinib
6. Change from baseline in histopathologic findings in blood and bone marrow (Time Frame - 18 months): Percentage change in mast cell infiltration in the bone marrow and percentage change in eosinophilia and monocytosis in the blood
7. Change in spleen and liver volume by imaging (Time Frame - 18 months): Percentage change
8. Change in Patient Global Impression of Severity (PGIS) scale (Time Frame - 18 months): 0 -10 points (higher values represent worse symptom outcomes)
9. Change in Patient Global Impression of Change (PGIC) scale (Time Frame - 18 months): 0 - 7 points (higher values represent better symptom outcomes)
10. Change in Mastocytosis Quality of Life Questionnaire (MC-QoL) (Time Frame - 18 months): 0 - 100 (higher values represent better symptom outcomes)